ZTS

Zoetis
Pharmaceuticals · Health Care · as of 2026-11-20
Last close
$80.32
-0.6% on the session
1-year return
-29.8%
+0.1% over six months
Volatility
38.6%
annualized, trailing year
Max drawdown
-46.7%
worst peak to trough, 1y
What the numbers say

Zoetis is a pharmaceuticals name in the health care sector. Over the past year it returned -29.8%, against +4.8% over three months and -1.4% over one. It trades 10.1% below its 200-day average, so recent moves have not repaired the longer downtrend. Annualized volatility of 38.6% is above the market's typical range.

Its worst peak-to-trough decline over the year was -46.7%, and it has traded a median $308M a day, the figure that decides whether a position can actually be entered and exited at posted prices. Its daily moves correlate 0.22 with the S&P 500 proxy, so it has been moving substantially on its own.

Where it ranks
Within Health Care#56 of 59
Stronger than 5% of its sector on the momentum profile
Across the whole index#377 of 497

How ZTS scores on all four profiles

Its standing on steadiness, defensiveness and rebound, plus the factor-by-factor breakdown behind each score, and its closest and least-correlated peers among 6 others in Pharmaceuticals.

Start a free 7-day trial
Full metrics
1 day-0.6%
1 week-4.2%
1 month-1.4%
3 months+4.8%
6 months+0.1%
1 year-29.8%
12-1 momentum-28.9%
Volatility (1y, annualized)38.6%
Max drawdown (1y)-46.7%
Distance vs 200-day average-10.1%
Return per unit of risk-0.77
Median daily dollar volume$308M
Free newsletter

Get ZTS when it shows up in a ranking

Two editions a weekday, free, ranked lists built from this same data, on whatever the market is talking about.

Everything on this page is computed from daily adjusted closing prices. It contains no earnings, balance-sheet, guidance or ownership data, and it is not a valuation. Nothing here is tailored to your circumstances or a recommendation to buy or sell. Past performance does not predict future results.